85 related articles for article (PubMed ID: 15676039)
1. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
Kappelhoff BS; Huitema AD; Crommentuyn KM; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
Br J Clin Pharmacol; 2005 Feb; 59(2):174-82. PubMed ID: 15676039
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.
Dickinson L; Boffito M; Back DJ; Khoo SH; Pozniak AL; Mugyenyi P; Merry C; Autar RS; Burger DM; Aarons LJ
J Antimicrob Chemother; 2008 Dec; 62(6):1344-55. PubMed ID: 18824460
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Lopinavir in Severely Malnourished HIV-infected Children and the Effect on Treatment Outcomes.
Archary M; Mcllleron H; Bobat R; La Russa P; Sibaya T; Wiesner L; Hennig S
Pediatr Infect Dis J; 2018 Apr; 37(4):349-355. PubMed ID: 29227461
[TBL] [Abstract][Full Text] [Related]
4. Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.
Schipani A; Egan D; Dickinson L; Davies G; Boffito M; Youle M; Khoo SH; Back DJ; Owen A
Antivir Ther; 2012; 17(5):861-8. PubMed ID: 22477766
[TBL] [Abstract][Full Text] [Related]
5. Clofazimine pharmacokinetics in HIV-infected adults with diarrhea: Implications of diarrheal disease on absorption of orally administered therapeutics.
Zhang CX; Conrad TM; Hermann D; Gordon MA; Houpt E; Iroh Tam PY; Jere KC; Nedi W; Operario DJ; Phulusa J; Quinnan GV; Sawyer LA; Barrett LK; Thole H; Toto N; Van Voorhis WC; Arnold SLM
CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):410-423. PubMed ID: 38164114
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Han K; Baker M; Lovern M; Paul P; Xiong Y; Patel P; Moore KP; Seal CS; Cutrell AG; D'Amico RD; Benn PD; Landovitz RJ; Marzinke MA; Spreen WR; Ford SL
Br J Clin Pharmacol; 2022 Oct; 88(10):4607-4622. PubMed ID: 35695476
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic analysis of doravirine in real-world people with HIV.
Thoueille P; Delarive L; Cavassini M; Buclin T; Decosterd LA; Marzolini C; Girardin FR; Guidi M;
Br J Clin Pharmacol; 2024 Apr; 90(4):1058-1065. PubMed ID: 37994177
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of Z-Endoxifen in Patients With Advanced Solid Tumors.
Koubek EJ; Ralya AT; Larson TR; McGovern RM; Buhrow SA; Covey JM; Adjei AA; Takebe N; Ames MM; Goetz MP; Reid JM
J Clin Pharmacol; 2022 Sep; 62(9):1121-1131. PubMed ID: 35358345
[TBL] [Abstract][Full Text] [Related]
9. Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC-92480), a novel cereblon E3 ligase modulator.
Wu F; Liu L; Gaudy A; Wang X; Carayannopoulos L; Pourdehnad M; Lamba M
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1473-1484. PubMed ID: 37705327
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics of Sertraline in Psychiatric and Substance Use Disorders.
Castillo CEC; Garibay SEM; Segovia RDCM; Guzmán SZ; Cook HJ; Contreras MO; Moreno SR
J Clin Pharmacol; 2024 May; ():. PubMed ID: 38720595
[TBL] [Abstract][Full Text] [Related]
11. Integrating Clopidogrel's First-Pass Effect in a Joint Semi-Physiological Population Pharmacokinetic Model of the Drug and Its Inactive Carboxylic Acid Metabolite.
Pejčić Z; Topić Vučenović V; Miljković B; Vučićević KM
Pharmaceutics; 2024 May; 16(5):. PubMed ID: 38794348
[TBL] [Abstract][Full Text] [Related]
12. Fundamental Pharmacokinetic Concepts and Their Clinical Relevance: Clearance, Zero Versus First Order and Nonlinear Pharmacokinetics.
Preskorn SH
J Psychiatr Pract; 2021 Sep; 27(5):380-383. PubMed ID: 34529604
[TBL] [Abstract][Full Text] [Related]
13. Metal-Promoted Heterocyclization: A Heterosynthetic Approach to Face a Pandemic Crisis.
Rossi FV; Gentili D; Marcantoni E
Molecules; 2021 Apr; 26(9):. PubMed ID: 33947170
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.
Moltó J; Estévez JA; Miranda C; Cedeño S; Clotet B; Valle M
Br J Clin Pharmacol; 2016 Dec; 82(6):1528-1538. PubMed ID: 27447851
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of antiretroviral drugs in older persons.
Schoen JC; Erlandson KM; Anderson PL
Expert Opin Drug Metab Toxicol; 2013 May; 9(5):573-88. PubMed ID: 23514375
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
17. Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin.
Zhang C; Denti P; Decloedt EH; Ren Y; Karlsson MO; McIlleron H
Br J Clin Pharmacol; 2013 Nov; 76(5):741-51. PubMed ID: 23432610
[TBL] [Abstract][Full Text] [Related]
18. Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.
Zhang C; Denti P; Decloedt E; Maartens G; Karlsson MO; Simonsson US; McIlleron H
Br J Clin Pharmacol; 2012 May; 73(5):758-67. PubMed ID: 22126409
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
